Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2023-10-05 Earnings Release
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Increase of the EBIT guidance
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc RELEASE' dated October 5, 2023, announcing an 'Increase of the EBIT guidance' for the fiscal year 2023. This is a material, non-public event disclosure required under MAR (Market Abuse Regulation) Article 17. It is not a full annual report (10-K), an interim report (IR), or a standard earnings release (ER) which typically contains finalized figures. Instead, it is a specific, immediate regulatory disclosure concerning a change in financial forecast. Since there is no specific code for 'Guidance Update' or 'Inside Information Disclosure', and given its nature as a mandatory, immediate regulatory announcement distributed via EQS, the most appropriate general category is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous mandatory disclosures that don't fit the primary financial report types. The document length (4717 chars) is short enough that it is not the full underlying report, but the announcement itself. FY 2023
2023-10-05 English
Biotest AG: Peter Janssen appointed new Chairman of the Board of Biotest AG
Board/Management Information Classification · 100% confidence The document is an 'Ad-hoc RELEASE' announcing a change in senior management: 'Peter Janssen appointed new Chairman of the Board of Biotest AG'. This directly corresponds to the definition of Board/Management Information (MANG), which covers 'Announcement of changes in the company's board of directors or senior management.' Although it is an ad-hoc release, the specific content dictates the classification over a general regulatory filing (RNS). The document length (5015 chars) is substantial enough to be the primary announcement, not just a pointer to a report.
2023-10-05 English
Biotest AG: Biotest receives approval for innovative immunoglobulin Yimmugo in the UK
Regulatory Filings Classification · 100% confidence The document is a press release disseminated via EQS News, announcing that Biotest AG has received regulatory approval for its product Yimmugo® in the UK. The keywords 'Regulatory Approval' and the nature of the announcement (a specific, non-periodic event concerning a product's market access) indicate a general corporate announcement rather than a formal financial filing like a 10-K, IR, or ER. Since it is a specific regulatory/product update that doesn't fit the definitions for DIRS, DIV, CAP, or MANG, and it is not a transcript (CT) or a presentation (IP), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it is a formal notification to the market about a regulatory milestone.
2023-09-21 English
Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin
Legal Proceedings Report Classification · 99% confidence The document is a press release titled "Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin." It announces a specific clinical trial milestone (treating the first patient) and provides details about the drug (trimodulin), the trial design (ESsCAPE phase III), and the medical condition (sCAP). This content is characteristic of an announcement regarding ongoing research and development activities, which often accompanies or precedes a formal financial report, but is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). Since it is a news announcement disseminated via EQS News, and it details operational/clinical progress rather than a change in management (MANG) or a specific financial event like a dividend (DIV) or capital change (CAP), it fits best as a general regulatory announcement or news item. Given the options, it is a specific operational update that doesn't fit the other specialized categories well. It is not a formal regulatory filing like a 10-K or an ER. It is a press release announcing clinical progress. In the absence of a specific 'Clinical Trial Update' category, 'Regulatory Filings' (RNS) serves as the best general category for corporate news disseminated through official channels that doesn't fit elsewhere, although 'ER' or 'MDA' might sometimes cover high-level operational news if it were tied to financial results. Since this is purely clinical trial news, RNS is the most appropriate fallback for a non-financial, non-governance, non-management specific announcement.
2023-09-12 English
Biotest AG: US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin Yimmugo
Legal Proceedings Report Classification · 99% confidence The document is a press release dated September 7, 2023, announcing that the US Food and Drug Administration (FDA) has accepted the marketing authorization application (BLA) for Biotest AG's immunoglobulin product, Yimmugo. This is a significant regulatory event concerning product approval status. It is not a full annual report (10-K), an interim report (IR), an earnings release (ER), or a transcript (CT). Since it details a specific regulatory milestone (acceptance of a BLA for review) and is presented as a formal news announcement disseminated via EQS News, it fits best under the general category for regulatory announcements that aren't specifically about insider trading, dividends, or shareholder votes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific regulatory update that doesn't match the other specialized codes like DVA, LTR, or DIV. It is a formal announcement of a regulatory step.
2023-09-07 English
Biotest AG: Biotest treats first shingles patient with Varitect CP in VARIZOSTA study
Regulatory Filings Classification · 100% confidence The document is a press release dated September 5, 2023, announcing that Biotest AG has treated the first patient in its VARIZOSTA study concerning the use of Varitect® CP for shingles. It details the study's purpose, scope, and the medical context. This type of announcement, which reports on clinical trial progress or study initiation, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate action categories (like DIV, CAP, SHA). It is a general corporate update related to product development and clinical activity. Since it is a specific announcement that doesn't match the other defined categories, the most appropriate fallback is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous regulatory or corporate news releases that aren't covered elsewhere.
2023-09-05 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.